NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
21/07/2026
Voltar para busca
Dado oficial do USPTO
CHONG KUN DANG
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
30
Atualização mais recente
21/07/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
12/06/2019
Data de registro
06/10/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
21/07/2026
Última transação
21/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
702
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
03
Localização do titular
Seoul, KR
Examinador
LEVINE, HOWARD B
Localização atual
Historical data usage
Titulares e representantes
Titulares
CHONG KUN DANG HOLDINGS CORP.
Representantes
Michael T. Smith BIRCH, STEWART, KOLASCH & BIRCH, LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Vitamin preparations; Antibiotic preparations; Pharmaceutical agents affecting digestive organs; Pharmaceutical preparations for treating respiratory diseases; Allergy medications; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations acting on the central nervous system; Cardiovascular agents for medical purposes; Amino acids for medical purposes; Dermatological pharmaceutical preparations; Ophthalmic preparations; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for immunity adjustment; Pharmaceutical preparationsantivirals; Tumor suppressing agents; Pharmaceutical preparations for treating hypertension; pharmaceutical preparations for the treatment of hyperlipidemia; Anti-inflammatories; Analgesics; Bacterial poisons; Pharmaceutical preparations for the treatment of cellular disorders; Pharmaceutical preparations for the treatment of bone diseases; Pharmaceutical preparations for use in urology; Vaccines; Nutritional supplementstonics and alternatives for medical purposes; Antibiotics; pharmaceutical preparation for the arthritis treatment; pharmaceutical preparation for the rheumarthritis treatment; Anti-cancer preparations; Pharmaceutical preparations for the prevention of cancer; Pharmaceutical preparations for the treatment of cancer; Health food supplement mainly based on lactic acid bacteria; Nutritional supplementsprobiotic compositions; Lactic acid bacteria in the form of capsules for medical purpose; Lactose for medical purposes; Powdered milk for babies; Calcium supplements; Powdered nutritional supplement drink mixes; Probiotic supplements; Pharmaceutical preparations for use in the treatment of diabetesanemiacardiovascular diseaseweight losshormone replacementnutritional deficienciesinfectious diseaseautoimmune diseasefatigueinflammationpainenvironmental toxicitiesheavy metal toxicities; Nutraceutical preparations for therapeutic or medical purposes in the treatment of gout; nutraceuticals for use as a dietary supplement; Anti-oxidant food supplements; Food supplementsanti-oxidants; Food supplements ; Dietary supplements; Medicated food supplements
Publicações
Histórico de despachos e eventos da marca no USPTO.
30 publicações encontradas
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
21/07/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
21/07/2026
E815
TEAS SECTION 8 & 15 RECEIVED
16/04/2026
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
06/10/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
06/10/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/09/2020
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
02/09/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/09/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/09/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
21/07/2020
PUBO
PUBLISHED FOR OPPOSITION
21/07/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/07/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/06/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/06/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/06/2020
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
10/06/2020
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
01/04/2020
GNSL
LETTER OF SUSPENSION E-MAILED
01/04/2020
CNSL
SUSPENSION LETTER WRITTEN
01/04/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/03/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/03/2020
ALIE
ASSIGNED TO LIE
09/03/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/03/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/09/2019
GNRT
NON-FINAL ACTION E-MAILED
05/09/2019
CNRT
NON-FINAL ACTION WRITTEN
05/09/2019
DOCK
ASSIGNED TO EXAMINER
04/09/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
25/06/2019
NWAP
NEW APPLICATION ENTERED
15/06/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CHONG KUN DANG ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.